A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.

被引：0

作者：

Yee, Andrew J.

Nadeem, Omar

Rosenblatt, Jacalyn

Bianchi, Giada

O'Donnell, Elizabeth

Branagan, Andrew R.

Harrington, Cynthia C.

Agyemang, Emerentia A.

Gammon, Marilyn T.

Lively, Kathleen J.

Packer, Lisette A.

Bernstein, Zachary S.

Lyons, Rebecca T.

Riadi, Manal

Rowell, Sean M.

Mcvey, Cailin

Goguen, Amy C.

Horick, Nora K.

Richardson, Paul G.

Raje, Noopur S.

机构：

[1] Harvard Med Sch, Massachusetts Gener Hosp Canc Ctr, Boston, MA USA

[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA

[4] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA

[5] Dana Farber Canc Inst, Boston, MA USA

[6] Massachusetts Gen Hosp, Boston, MA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8012

引用

页数：1